Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific t-cell response

Journal of Immunotherapy

Volumn 24, Issue 5, 2001, Pages 420-429

  Nguyen, Christophe L ^a   Bui, Joe T ^a   Demcheva, Marina ^b   Vournakis, John N ^b   Cole, David J ^b   Gillanders, William E ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cytotoxic T Lymphocyte; Dendritic cells; Granulocyte macrophage colony stimulating factor; Vaccination

Indexed keywords

CANCER VACCINE; F2 GEL MATRIX; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GEL; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; TRANSGENIC MOUSE;

ACETYLGLUCOSAMINE; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; DELAYED-ACTION PREPARATIONS; GELS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; SPLEEN; T-LYMPHOCYTES; THYMOMA; TUMOR CELLS, CULTURED;

EID: 0034764675     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200109000-00004     Document Type: Article

References (35)

1. Kedl RM, Mescher MF. Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumor. J Immunol 1997; 159: 650-3.
2. Cheever MA, Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev 1997; 157: 177-94.
3. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am 1995; 1: 90.
4. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1998; 319: 1676-80.
5. Aichele P, Brduscha-Riem K, Zinkernagel RM, et al. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182: 261-6.
6. Toes RE, Blom RJ, Offringa R, et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996; 156: 3911-8.
7. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 1998; 16: 1025-31.
8. Pardoll DM. Cancer vaccines. Nat Med 1998; 4: 525-31.
9. Brewer JM, Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell Mol Ther 1997; 3: 233-46.
10. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-84.
11. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
12. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
13. Bowne WB, Wolchok JD, Hawkins WG, et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther 1999; 5: 217-25.
14. Ahlers JD, Dunlop N, Alling DW, et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 1997; 158: 3947-58.
15. Nasi ML, Lieberman P, Busam KJ, et al. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther 1999; 5: 139-44.
16. Maitre N, Brown JM, Demcheva M, et al. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res 1999; 5: 1173-82.
17. Hogquist KA, Jameson SC, Heath WR, et al. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27.
18. Kearney ER, Pape KA, Loh DY, et al. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994; 1: 327-39.
19. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1998; 54: 777-85.
20. Pure E, Inaba K, Crowley MT, et al. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. J Exp Med 1990; 172: 1459-69.
21. Dieu-Nosjean M, Massacrier C, Homey B, et al. Macrophage inflammatory protein 3 is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000; 192: 705-17.
22. Ruedl C, Kopf M, Bachmann MF. CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J Exp Med 1999; 189: 1875-84.
23. Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999; 29: 592-601.
24. Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol 1999; 29: 602-7.
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
26. Shrikant P, Mescher MF. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 1999; 162: 2858-66.
27. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-83.
28. Sarzotti M, Robbins DS, Hoffman PM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 1996; 271: 1726-8.
29. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996; 271: 1723-6.
30. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity in neonatal mice. Science 1996; 271: 1728-30.
31. Stahl PD, Ezekowitz RA. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998; 10: 50-5.
32. Yamamoto Y, Klein TW, Friedman H. Involvement of mannose receptor in cytokine interleukin-1-beta, IL-6, and granulocyte-macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1-beta, MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect Immun 1997; 65: 1077-82.
33. Shibata Y, Foster LA, Metzger WJ, et al. Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-d-glucosamine, in mice. Infect Immun 1997; 65: 1734-41.
34. Fukao T, Matsuda S, Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol 2000; 164: 64-71.
35. Okamoto I, Kohno K, Tanimoto T, et al. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. J Immunol 1999; 162: 3202-11.